Denali Therapeutics Inc. financial data

Symbol
DNLI on Nasdaq
Location
161 Oyster Point Blvd., South San Francisco, CA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 949 % -20.3%
Debt-to-equity 13.1 % +35.5%
Return On Equity -46.3 % -40.7%
Return On Assets -41 % -36.4%
Operating Margin -65.5 % +83.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 147M shares +1.9%
Common Stock, Shares, Outstanding 147M shares +1.94%
Entity Public Float 1.9B USD -5%
Common Stock, Value, Issued 1.71M USD +1.48%
Weighted Average Number of Shares Outstanding, Basic 172M shares +1.75%
Weighted Average Number of Shares Outstanding, Diluted 172M shares +1.75%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 295M USD +191%
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 421M USD +4.01%
General and Administrative Expense 127M USD +27%
Operating Income (Loss) -548M USD -11.8%
Nonoperating Income (Expense) 51.5M USD +249%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -499M USD -16.7%
Earnings Per Share, Basic -2 USD/shares -4.68%
Earnings Per Share, Diluted -2 USD/shares -6.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 91M USD +0.36%
Marketable Securities, Current 757M USD +1.52%
Assets, Current 883M USD +1.58%
Property, Plant and Equipment, Net 53.7M USD +5.73%
Operating Lease, Right-of-Use Asset 20M USD -15.5%
Other Assets, Noncurrent 25.1M USD -5.21%
Assets 1.06B USD -27.4%
Accounts Payable, Current 6.75M USD -29.7%
Employee-related Liabilities, Current 18.4M USD +23.4%
Accrued Liabilities, Current 4.94M USD +2.34%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 90.1M USD +3.51%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 29.7M USD -23.6%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 129M USD -4.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.1M USD -80.1%
Retained Earnings (Accumulated Deficit) -1.92B USD -35%
Stockholders' Equity Attributable to Parent 926M USD -29.8%
Liabilities and Equity 1.06B USD -27.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -131M USD -15.7%
Net Cash Provided by (Used in) Financing Activities -3.76M USD -101%
Net Cash Provided by (Used in) Investing Activities 18.7M USD
Common Stock, Shares Authorized 400M shares 0%
Common Stock, Shares, Issued 147M shares +1.94%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -116M USD -75.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 94.1M USD +2.02%
Deferred Tax Assets, Valuation Allowance 488M USD +29.8%
Deferred Tax Assets, Gross 504M USD +30%
Operating Lease, Liability 38.9M USD -17.1%
Payments to Acquire Property, Plant, and Equipment 5.08M USD +136%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -503M USD -19.4%
Lessee, Operating Lease, Liability, to be Paid 45.1M USD -20.6%
Property, Plant and Equipment, Gross 107M USD +17.1%
Operating Lease, Liability, Current 9.16M USD +14%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.6M USD +3.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 12.2M USD +3.3%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 6.28M USD -36.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 13M USD +3.31%
Deferred Tax Assets, Operating Loss Carryforwards 113M USD +27%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 40M shares 0%
Unrecognized Tax Benefits 33.8M USD +29%
Lessee, Operating Lease, Liability, to be Paid, Year Four 4.38M USD -66.3%
Operating Lease, Payments 11.7M USD +3.29%
Additional Paid in Capital 2.85B USD +4.05%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.33M USD +7.54%
Deferred Tax Assets, Net of Valuation Allowance 16.3M USD +36.5%
Share-based Payment Arrangement, Expense 101M USD -2.92%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%